New Science Ventures

General contacts
Investor type

PE / VC

Founded

2004

AUM

$600 M

Location

London, England, United Kingdom

Investment Ticket

$10-50 m

Investment Stage

Seed Series A Series B Late Stage (Series C+)

Region of investment

North America Europe
Investor profile last updated: 12 August, 2026

Profile

New Science Ventures, LLC (NSV) is a venture capital firm based in Connecticut and London. They invest in companies employing novel scientific approaches within the life sciences and information technology sectors. Known for creating value through breakthrough science, NSV distinguishes itself by focusing on significant unmet needs, leveraging both early and late-stage investments to support innovative technologies in its targeted fields.

NSV targets the life sciences and information technology sectors, with investments covering a wide range of sub-sectors. They provide funding for early-stage through late-stage companies, although specific check sizes are not mentioned. Their geographical focus spans multiple regions due to their multiple bases of operation.

The firm has invested in companies such as Trellis Bioscience, known for developing monoclonal antibodies to treat infectious diseases, and Antevia Networks, a telecom equipment vendor focused on private 5G networks. Glydways, a global leader in Automated Transit Networks, is another notable investment illustrating their diversified venture strategy in technology-oriented sectors.

Industry

HealthTech Life Sciences Telecommunications Biotechnology Healthcare Services Medical Devices Pharmaceuticals Software AI Internet of Things (IoT) Semiconductors / Chips

Contacts

Name
Title
Email
Social Networks
avatar
Andrew Abrams Partner
Partner
a•••@•••
LinkedIn
avatar
Brenda Marex Partner and Chief Financial Officer
Partner and Chief Financial Officer
b•••@•••
Upgrade to see contacts
avatar
y0OhwBk2WnEU7qXd y0OhwBk2WnEU7qXd
y0OhwBk2WnEU7qXd
[email protected]
linkedin twitter
avatar
y0OhwBk2WnEU7qXd y0OhwBk2WnEU7qXd
y0OhwBk2WnEU7qXd
[email protected]
linkedin twitter
avatar
y0OhwBk2WnEU7qXd y0OhwBk2WnEU7qXd
y0OhwBk2WnEU7qXd
[email protected]
linkedin twitter
Investment-team contacts for New Science Ventures — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about New Science Ventures

New Science Ventures is a venture capital and private equity firm. It backs companies at Seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.
New Science Ventures is located in London, England, United Kingdom.
New Science Ventures was founded in 2004.
New Science Ventures invests in companies and startups in HealthTech, Life Sciences, Telecommunications, Biotechnology, Healthcare Services, Medical Devices, Pharmaceuticals, Software, AI, Internet of Things (IoT), Semiconductors / Chips.
New Science Ventures invests in companies and startups in North America, Europe.
New Science Ventures invests in companies and startups at Seed, Series A, Series B, Late Stage (Series C+).
New Science Ventures usually invests $10-50 m on average.
New Science Ventures has around $600m assets under management.
New Science Ventures can be reached through its website newscienceventures.com and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for New Science Ventures — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query New Science Ventures directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 12 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.